Navigation Links
FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
Date:1/18/2008

f any intensity that occurred at a higher rate than placebo were rash (16.9 percent vs. 9.3 percent) and nausea (13.9 percent vs. 11.1 percent). The most common treatment-emergent adverse reactions (Grade 2-4) that occurred in greater than or equal to two percent of patients receiving an INTELENCE-containing regimen were diarrhea, nausea, abdominal pain, vomiting, fatigue, peripheral neuropathy, headache, rash, and hypertension.

Additional Important Safety Information

INTELENCE does not cure HIV infection or AIDS, and does not prevent passing HIV to others.

-- Severe and potentially life-threatening skin reactions, including

Stevens-Johnson Syndrome, hypersensitivity reaction, and erythema

multiforme, have occurred (< 0.1 percent) in patients taking INTELENCE.

Treatment with INTELENCE should be discontinued and appropriate therapy

initiated if severe rash develops.

-- In general, in clinical trials, rash was mild to moderate, occurred

primarily in the second week of therapy, and was infrequent after Week

4. Rash generally resolved within 1-2 weeks on continued therapy.

Discontinuation rate due to rash was two percent.

-- Redistribution and/or accumulation of body fat have been observed in

patients receiving antiretroviral (ARV) therapy. The causal

relationship, mechanism, and long-term consequences of these events

have not been established.

-- Immune reconstitution syndrome has been reported in patients treated

with ARV therapy, including INTELENCE.

-- INTELENCE should be used with caution in patients with severe hepatic

impairment (Child-Pugh class C) as pharmacokinetics of INTELENCE have

not been evaluated in these patients.

Drug Interactions

-- INTELENCE should not be co-administered with the following ARVs:

tipranavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavi
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
2. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
3. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
4. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
5. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
6. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
7. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
8. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
9. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
10. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
11. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... HealthTronics, Inc ., a ... products and services, announced that a poster related ... versus external beam radiotherapy (EBRT) is being presented ... Association (MAAUA) Annual Meeting in Baltimore, Maryland September ... Cryosurgery and External Beam Radiation as Treatments for ...
(Date:9/18/2014)... , September 18, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced ... Materials - Global Strategic Business Report" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the ... US$ Million by the following Product ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Human Albumin Industry Report 2014" report ... Albumin Industry Report 2014 is a professional and in-depth ... albumin industry. The report provides a basic ... industry chain structure. The human albumin market analysis is ...
(Date:9/18/2014)...  Neogen Corporation (Nasdaq: NEOG ) announced ... with Merck Animal Health to market Neogen,s Igenity ® ... Dairy Heifer Program consists of genomic tests that offer ... of replacement dairy heifers. The genomic tests can be ... an excellent tool in the decision-making process for breeding ...
Breaking Biology Technology:HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Merck Animal Health to market Neogen's dairy genomic program 2
... Mich., Sept. 26 MichBio, the,association for Michigan,s life ... held October 16 in East Lansing. Michigan State,University has ... event on,its campus. Career Day is intended to introduce ... educational and career opportunities in,the life sciences. It takes ...
... HILL, N.C., Sept. 26 The landscape of ... the advent of,transparency guidelines. Half of global publications ... publications leaders foresee a shift,to medical groups to ... by Best Practices, LLC. In a benchmarking ...
... Mylan Laboratories Inc.,(NYSE: MYL ) will host ... acquisition. Pending the closing, the investor day will take ... Robert J. Coury, Mylan,s,Vice Chairman and Chief Executive Officer, ... Generics and Matrix Laboratories will,provide a detailed financial and ...
Cached Biology Technology:MichBio Announces Student Career Day at Michigan State University 2Industry Executives Finding Value in Shift of Scientific Publications 2
(Date:9/18/2014)... ultimate form of camouflage: you don,t just blend in, ... not as uncommon as you might think. Kathryn Feller, ... that the larval life stages of many marine species ... anatomy that most creatures cannot make transparent. Feller explains ... each individual eye unit with an opaque pigment to ...
(Date:9/17/2014)... instrumental in the creation of the Santa Ana Wildfire ... fire threat potential of the powerful, hot, dry Santa ... inferno. The index was introduced Sept. 17 by the ... Diego Gas and Electric. , The index includes four ... be used to help fire agencies and other emergency ...
(Date:9/17/2014)... SAN DIEGO, Calif. (Sept. 17, 2014) A rare genetic ... autism, according to a recent joint investigation by researchers ... California, San Diego. In addition to suggesting better treatment ... offers more clues into the genetic underpinnings of autism., ... to the National Institutes of Health. It occurs in ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2A link between Jacobsen syndrome and autism 2
... and Environmental Engineering suggests how aquatic plants in rivers and ... large areas of ocean coastal waters. This work, ... of Fluid Mechanics (JFM), describes the physics of water flow ... to environmental engineering. This new understanding can be used to ...
... and Budget evaluates R&D programs at the U.S. Environmental ... asks about many aspects of their research, including its ... and an "ineffective" rating can have serious adverse consequences ... meeting OMB,s requirements to measure and demonstrate efficiency, EPA ...
... US national grids has enabled UCL (University College London) scientists ... a key protein used by the lethal virus. The method ... action could one day be used to tailor personal ... their drugs. The study, published online today in the ...
Cached Biology News:River plants may play major role in health of ocean coastal waters 2Virtual human in HIV drug simulation 2
Rabbit polyclonal to SUR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide Entrez Gene ID: 6833 Swiss Protein ID: Q09428...
... ARG. Vasopressin The antibody blocks ... are found in the paraventricular and ... throughout the hypothalmus in rat brain ... Immunogen: Arginine Vasopression ...
Pronase Reagent...
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
Biology Products: